NASDAQ:NKTR
Nektar Therapeutics
Nektar Therapeutics's revenue fell 43.9% in fiscal 2025 to $55.2M while operating margin fell to −253.7%. Free cash flow was −$208.7M, −377.8% of revenue, and the diluted share count rose 23.0%.Summary generated from Nektar Therapeutics's SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$55.2M
Revenue growth−43.9%
Revenue, 5-yr CAGR−18.4%
Gross margin100.0%
Operating margin−253.7%
Net margin−297.1%
ROICn/a
Return on equity−217.9%
Debt / equityn/a
Free cash flow−$208.7M
FCF margin−377.8%
Share count change+23.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 102 | 92 | 90 | 98 | 55 |
| Operating income | −446 | −376 | −264 | −105 | −140 |
| Net income | −524 | −368 | −276 | −119 | −164 |
| Free cash flow | −428 | −310 | −193 | −177 | −209 |
Recent filings
- 8-KRegulation FD disclosure
Oct 1, 2026 - 4Insider transaction report
Sep 25, 2026 - 4Insider transaction report
Sep 25, 2026 - 8-KOther events
Sep 25, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 5, 2026